These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 1664434)
41. Mechanism of action of foscarnet against viral polymerases. Crumpacker CS Am J Med; 1992 Feb; 92(2A):3S-7S. PubMed ID: 1371038 [TBL] [Abstract][Full Text] [Related]
42. N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity. Shi J; Mathew JS; Tharnish PM; Rachakonda S; Pai SB; Adams M; Grier JP; Gallagher K; Zhang H; Wu JT; Shi G; Geleziunas R; Erickson-Viitanen S; Stuyver L; Otto MJ; Watanabe KA; Schinazi RF Antivir Chem Chemother; 2003 Mar; 14(2):81-90. PubMed ID: 12856919 [TBL] [Abstract][Full Text] [Related]
43. In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. Montefiori DC; Robinson WE; Mitchell WM AIDS Res Hum Retroviruses; 1989 Apr; 5(2):193-203. PubMed ID: 2469450 [TBL] [Abstract][Full Text] [Related]
44. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801 [TBL] [Abstract][Full Text] [Related]
45. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds. Schinazi RF; Nahmias AJ Am J Med; 1982 Jul; 73(1A):40-8. PubMed ID: 6285731 [TBL] [Abstract][Full Text] [Related]
46. Rapid assessment of antiviral activity and cytotoxicity of silver nanoparticles using a novel application of the tetrazolium-based colorimetric assay. Trefry JC; Wooley DP J Virol Methods; 2012 Jul; 183(1):19-24. PubMed ID: 22465243 [TBL] [Abstract][Full Text] [Related]
47. Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. Schott H; Hamprecht K; Schott S; Schott TC; Schwendener RA Bioorg Med Chem; 2009 Jan; 17(1):303-10. PubMed ID: 19010684 [TBL] [Abstract][Full Text] [Related]
48. Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. Vogt MW; Durno AG; Chou TC; Coleman LA; Paradis TJ; Schooley RT; Kaplan JC; Hirsch MS J Infect Dis; 1988 Aug; 158(2):378-85. PubMed ID: 2841378 [TBL] [Abstract][Full Text] [Related]
49. [Anti-HIV therapy (1987-1994): from nothing to confusion]. Lissen E Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285 [No Abstract] [Full Text] [Related]
50. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. Palmer S; Alaeus A; Albert J; Cox S AIDS Res Hum Retroviruses; 1998 Jan; 14(2):157-62. PubMed ID: 9462926 [TBL] [Abstract][Full Text] [Related]
51. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375 [TBL] [Abstract][Full Text] [Related]
52. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. Gao Q; Gu Z; Salomon H; Nagai K; Parniak MA; Wainberg MA Arch Virol; 1994; 136(1-2):111-22. PubMed ID: 8002779 [TBL] [Abstract][Full Text] [Related]
53. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Larder BA; Kemp SD; Purifoy DJ Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4803-7. PubMed ID: 2472634 [TBL] [Abstract][Full Text] [Related]
54. Differential susceptibility of retroviruses to nucleoside analogues. Rosenblum LL; Patton G; Grigg AR; Frater AJ; Cain D; Erlwein O; Hill CL; Clarke JR; McClure MO Antivir Chem Chemother; 2001 Mar; 12(2):91-7. PubMed ID: 11527046 [TBL] [Abstract][Full Text] [Related]
55. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1. Cox SW; Albert J; Wahlberg J; Uhlén M; Wahren B AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1229-34. PubMed ID: 1520536 [TBL] [Abstract][Full Text] [Related]
58. The treatment of HIV infection. Richman DD AIDS; 1988; 2 Suppl 1():S137-42. PubMed ID: 2852501 [No Abstract] [Full Text] [Related]
59. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. Hirsch MS J Infect Dis; 1990 May; 161(5):845-57. PubMed ID: 1691243 [TBL] [Abstract][Full Text] [Related]
60. A tetrazolium-based colorimetric assay for quantification of HIV-1-induced cytopathogenicity in monocyte-macrophages exposed to macrophage-colony-stimulating factor. Bergamini A; Perno CF; Capozzi M; Mannella E; Salanitro A; Caliò R; Rocchi G J Virol Methods; 1992 Dec; 40(3):275-86. PubMed ID: 1474134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]